

# Genetic Analysis of HIV Type 1 Strains from Newly Infected Untreated Patients in Cyprus: High Genetic Diversity and Low Prevalence of Drug Resistance

Ioanna Kousiappa,<sup>1</sup> David A.M.C. van de Vijver,<sup>2</sup> Ioannis Demetriades,<sup>3</sup> and Leondios G. Kostrikis<sup>1</sup>

## Abstract

The molecular epidemiology of HIV-1 infection was first studied in Cyprus in the mid-1990s, but the extent of HIV-1 diversity and the prevalence of drug resistance have remained elusive. In an effort to address this issue, the present study examined HIV-1 strains isolated from 37 newly diagnosed untreated HIV-1 patients, representing 72% of the total number of newly diagnosed and drug-naive patients in the period 2003 to 2006. DNA sequences encoding the *gag* (p17, p24, p2, p7, p1, and p6), *pol* (protease and reverse transcriptase), and *env* (gp160) regions were amplified by RT-PCR from plasma HIV-1 RNA from all patients and sequenced using a newly designed methodology. All amplified products were studied according to established genetic methodologies to determine the genetic subtype and the prevalence of drug-resistance-associated mutations to currently available antiretroviral drugs. Analyses of the obtained viral sequences indicated that subtype A was the most common subtype present and accounted for 38% of the infections followed by subtype B (35%), subtype C (13%), CRF02\_AG (8%), and subtypes D and CRF01\_AE (3% each). One patient (2.7%) had an M41L/M and another patient (2.7%) an M184V amino acid substitution in the reverse transcriptase (RT) associated with high-level resistance to RT inhibitors. There were no patients with resistant mutations to protease inhibitors (PI). Additionally, one patient (2.7%) had an L44M amino acid substitution within the HR1 region of gp41 conferring resistance to the enfuvirtide (T20) fusion inhibitor. Similar to results of the 1994 molecular epidemiological study, these data demonstrate the extensive heterogeneity of HIV-1 infection in Cyprus and the low prevalence of transmitted resistance to current HIV-1 antiretroviral drugs. Taken together, these findings demonstrate that HIV-1 infection in Cyprus is being replenished by a continuous influx of new strains from many countries, establishing an ever-evolving and polyphyletic infection in the island.

## Introduction

**H**UMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) is able to develop extensive genetic diversity, and by this means acquires mutations to resist inhibitory pressures by antiretroviral drugs. The global genetic diversity of HIV-1 and the spread of variants with resistance to current antiretroviral drugs are being studied through the collective efforts of multinational consortia and many other groups worldwide. Genetic analysis of HIV-1 strains isolated from many countries thus far has revealed nine distinct phylogenetic subtypes (A–D, F–H, J, and K) and at least 21 intersubtype circulating

recombinants forms (CRFs) among the isolates within the major group, M.<sup>1–6</sup> The constant tracking of the genetic diversity of HIV-1 infection has important implications for monitoring the global evolution of HIV-1 and ensuring the efficacy of viral RNA quantitation methods<sup>7–12</sup> and future vaccine development.<sup>13–16</sup> The reported prevalence of HIV-1 infection in Cyprus is lower (about 0.05%) than other European countries and is comparable to that of neighboring countries in the eastern Mediterranean region.<sup>17–21</sup> The first AIDS patient in Cyprus was reported in 1987 and the first molecular epidemiological study of HIV-1 infection in Cyprus was conducted in 1994.<sup>22</sup> Based on phylogenetic analyses of

<sup>1</sup>Department of Biological Sciences, University of Cyprus, 1678 Nicosia, Cyprus.

<sup>2</sup>Department of Virology, Erasmus MC, University Medical Centre Rotterdam, 3000 CA Rotterdam, The Netherlands.

<sup>3</sup>AIDS Clinic, Larnaca General Hospital, 6043 Larnaca, Cyprus.

obtained viral sequences encoding the C2 to V3 *env* gp120 from 24 patients infected from 1987 to 1994, subtype B was identified as the most prevalent subtype accounting for 63% of the infections, followed by subtype A (21%), subtype F (8%), and subtypes C and I (4% each).<sup>22</sup> Subtype I was later determined to be a complex mosaic comprising subtypes A, G, and I and has been named CRF04\_cpx.<sup>23</sup>

Combination antiretroviral therapy (cART) with recently approved highly active antiretroviral drugs has significantly improved the quality of life for HIV-infected patients.<sup>3</sup> However, infection with drug-resistant HIV-1 variants with reduced susceptibility to drugs can impair the response to cART and may have important implications for the clinical management of HIV-1-infected patients. Based on reported worldwide studies, the prevalence of transmitted drug-resistant HIV-1 variants ranges from 1.4% to 28.9%.<sup>3,24–30</sup> The prevalence of HIV-1 variants with drug-resistant mutations in newly diagnosed individuals from western Europe and Israel is approximately 9%.<sup>31</sup> cART using protease and reverse transcriptase inhibitors was first introduced in the late 1990s, and until now there have been no studies investigating the extent and impact of transmission of drug-resistant HIV-1 variants in Cyprus. As part of a continuing effort to monitor the genetic diversity of HIV in Cyprus, in this study we determined the genetic diversity and the prevalence of antiretroviral drug resistance mutations among HIV-1 strains isolated from 37 newly diagnosed untreated HIV-1 patients, representing 72% of the total number of newly diagnosed patients in the period 2003 to 2006.

## Materials and Methods

### Study subjects

Between 2003 and 2006 blood samples were obtained from 37 HIV-1 newly diagnosed patients at the Cyprus Reference AIDS Clinic, Larnaca National Hospital, with the informed consent of all participants and the approval of the Cyprus National Bioethics Committee. All patients were living permanently in Cyprus at the time of sampling. The majority of study subjects were Greek-Cypriots, although a number reported traveling or living abroad in the past. The HIV-1 serostatus of each subject was previously established by commercial enzyme-linked immunoassay and confirmed by Western blotting. Blood was drawn within 3 months of HIV-1 diagnosis. A description of the clinical profile of each patient is presented in Table 1. All blood samples were processed at the Laboratory of Biotechnology and Molecular Virology of the University of Cyprus on the same day of sampling.

### HIV-1 plasma RNA and cell-associated DNA isolation

Patients' blood (16 ml) was collected in CPT tubes (Becton Dickinson, Annapolis, MD) and peripheral blood mononuclear cells (PBMCs) and plasma were isolated using the CPT vacutainer procedure. HIV-1 RNA was extracted from 200  $\mu$ l plasma and genomic DNA from about 10<sup>7</sup> uncultured PBMCs using QIAamp silica-gel-membrane technology with the QIAamp UltraSens Virus Kit and QIAamp DNA Blood Mini Kit, respectively (Qiagen, Valencia, CA). Genomic DNA was quantified by ultraviolet (UV) absorbance spectrophotometry using the Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE).

### PCR and sequencing

HIV-1 sequences encoding approximately 1722 bp of the *gag* region, 1461 bp of the *pol* (*protease and RT*) region, and 2927 bp of the *env* (*gp160*) region were amplified from each sample by nested polymerase chain reaction (PCR) using PBMC-associated HIV-1 DNA. For any samples where the PCR product of genomic DNA was problematic, reverse transcription nested PCR (RT-PCR) using plasma HIV-1 RNA was performed instead. Primers used in the first round of PCR were 623 and 2501 for *gag*,<sup>32</sup> 1832 and 3583 for *pol* (*protease and RT*), and 5955 and 9181 for *env* (*gp160*). Inner primers were 684 and 2406 for *gag*, 2078–3539 for *pol* (*protease and RT*), and 6111 and JL88 for *env* (*gp160*). The primer positions corresponding to the HXB2 strain (accession number K03455) are described in Table 2. In the first round of PCR, approximately 60–100 ng of patient PBMC DNA was used, as were 20 pmol of each primer and 1.1X Platinum PCR SuperMix (Invitrogen Corp., San Diego, CA) in a 50- $\mu$ l volume. DNA amplifications were carried out in an Eppendorf Master Cycler (Eppendorf, Hamburg, Germany). For *gag* amplification, the thermocycling conditions were one cycle at 94°C for 2 min, 40 cycles at 94°C for 20 s, 53°C for 30 s, 72°C for 2 min, and one cycle at 72°C for 7 min. For *pol* (*protease and RT*) and *env* (*gp160*), the thermocycling conditions were the same except the hybridization temperatures were 52 and 54°C, respectively. In the second round of PCR, 3  $\mu$ l samples of primary reaction products were used, along with 20 pmol of each primer and 1.1X Platinum PCR SuperMix (Invitrogen Corp., San Diego, CA) in a 50- $\mu$ l volume. The amplification conditions were identical to those described for the first round of PCR, except the hybridization temperatures were 56°C for *gag* and 52°C for *pol* (*protease and RT*) and *env* (*gp160*) and the polymerization times were 2.20 min for *gag*, 2 min for *pol* (*protease and RT*), and 3.20 min for *env* (*gp160*). The detailed experimental method for the amplification of the *pol* (*protease and RT*) region by RT-PCR using plasma HIV-1 RNA is described below in this section. For *gag* and *env* RT-PCR amplification, the experimental conditions were the same as those described in the nested PCR methods with the following modifications: the Invitrogen SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity was used instead of the 1.1X Platinum PCR SuperMix according to the manufacturer's specifications (Invitrogen Corp., San Diego, CA); in the first round *env* RT-PCR amplification there was an additional reverse transcription cycle at 54°C for 1 h; for *gag* RT-PCR amplification, the reverse transcription cycle was at 52°C for 1 h; in both RT-PCR amplifications, the polymerization temperature was 68°C instead of 72°C.

Amplified products from the second-round PCR were purified using the QIAquick PCR purification kit (Qiagen, Valencia, CA), their lengths were analyzed by 1% agarose gel electrophoresis, and the concentrations were quantified by UV absorbance spectrophotometry using the Nanodrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE). In each sample, the DNA sequences encoding the *gag*, *pol* (*protease and RT*), and *env* (*gp160*) regions were determined by directly sequencing both complementary strands in separate reactions, using the second-round-amplified PCR product as the template and sequencing primers as follows (Table 2): primers 684, 1173, 1985, 2406 for *gag*; 2136, 3462 for *pol* (*protease and RT*); and 6111, 6438, 6858,

TABLE 1. CLINICAL AND EPIDEMIOLOGICAL INFORMATION FOR STUDY PATIENTS

Patient <sup>a</sup>	Sex <sup>b</sup>	Age (years)	Weeks since diagnosis <sup>c</sup>	Country of origin <sup>a</sup>	Transmission risk group <sup>e</sup>	CD4 (cells/mm <sup>3</sup> )	Plasma HIV-1 RNA (copies × 10 <sup>4</sup> /ml)	Epidemiological information <sup>f</sup>
CY004	M	47	1	Cyprus	MSM	363	1.3	N/A
CY005	M	32	1	Cyprus	MSM	357	2.0	N/A
CY006	M	33	1	Cyprus	MSM	593	2.9	N/A
CY007	M	36	1	Cameroon	MSM	842	1.2	Political refugee from Cameroon
CY008	F	36	1	Cyprus	HSX	556	0.2	N/A
CY009	M	24	1	Cyprus	MSM	290	2.7	HBV positive
CY010	M	45	1	Cyprus	MSM	442	12.0	N/A
CY012	M	30	8	Cyprus	MSM	461	30.0	N/A
CY013	M	54	1	Cyprus	MSM	79	100.3	N/A
CY014	M	N/A	1	Cyprus	MSM	671	1.7	N/A
CY015	F	19	4	Georgia	HSX	369	7.7	Possibly infected by heterosexual partner CY009
CY016	M	59	3	Cyprus	HSX	202	17.0	N/A
CY035	M	27	2	Cyprus	MSM	191	55.0	Diagnosed with <i>Pneumocystis carinii</i> pneumonia
CY048	M	30	1	Burkina-Faso	MSM	181	27.0	Political refugee from Burkina-Faso
CY057	F	28	1	Georgia	HSX	N/A	2.8	Heterosexual partner of CY058; HCV positive
CY058	M	34	1	Georgia	HSX	N/A	3.2	Heterosexual partner of CY057; HCV positive
CY066	M	28	1	Cyprus	MSM	N/A	0.6	N/A
CY073	M	26	1	Pakistan	Unknown	425	6.4	Diagnosed with tuberculosis lymphadenopathy
CY089	F	20	1	Cyprus	HSX	262	5.6	Possibly infected by heterosexual partner CY008
CY109	M	36	12	Cyprus	MSM	339	2.3	Possible infected by homosexual contact in Germany
CY111	F	37	1	Sweden	HSX	32	200.0	Heterosexual partner of CY112
CY112	M	N/A	1	U.K.	HSX	292	6.0	Heterosexual partner of CY111; HCV positive
CY142	M	53	1	Cyprus	MSM	32	31.0	Diagnosed with pneumonia recurrent
CY153	M	20	2	Cyprus	MSM	223	5.9	Diagnosed with pneumonia recurrent
CY158	M	37	1	Burkina-Faso	OHPC	78	6.5	Political refugee from Burkina-Faso
CY159	M	34	4	Cyprus	MSM	1390	0.2	N/A
CY166	M	57	4	Cyprus	HSX	134	100.0	Diagnosed with non-Hodgkin's lymphoma
CY169	F	33	1	Georgia	HSX	72	12.0	Heterosexual partner of CY171; currently on treatment for lymphoma
CY170	M	36	2	Cyprus	HSX	473	13.0	Diagnosed with infectious mononucleosis and herpes genital
CY171	M	47	2	Cyprus	HSX	447	11.0	Heterosexual partner of CY169, diagnosed with gonorrhoea
CY172	M	24	12	Cameroon	HSX	363	8.8	Political refugee from Cameroon
CY173	F	27	4	Ukraine	HSX	598	1.8	Infected by heterosexual partner CY170 six months before
CY175	M	30	8	Cyprus	HSX	320	1.2	Heterosexual partner of CY176
CY176	F	24	4	Ethiopia	HSX	595	2.1	Heterosexual partner of CY175
CY177	M	47	8	Cyprus	MSM	641	4.7	HBV positive
CY178	M	42	1	Cyprus	MSM	785	0.1	N/A
CY179	M	36	2	Cyprus	HSX	498	3.3	N/A

<sup>a</sup>Indicates the laboratory code for each study subject.

<sup>b</sup>F, female; M, male.

<sup>c</sup>Indicates the duration from the first known positive HIV antibody test.

<sup>d</sup>Country of birth of the study subjects.

<sup>e</sup>MSM, men who have sex with men; HSX, heterosexual contact; OHPC, origin from a high prevalence country.

<sup>f</sup>Information provided by the study subjects. N/A, not available; HBV, hepatitis B virus; HCV, hepatitis C virus.

TABLE 2. PCR AND SEQUENCING PRIMERS

Designation <sup>a</sup>	Target gene	Sequence <sup>b</sup>	Position <sup>c</sup>	Amplicon length (nts)	Reference <sup>d</sup>
<b>PCR primers</b>					
623 (F)	<i>gag</i>	AAATCTCTAGCAGTGGCGCCCGAA	623–646	1878	32
2501 (R)	<i>gag</i>	GTTGACAGGTGTAGGTCCCTAC	2481–2501		32
684 (F) <sup>e</sup>	<i>gag</i>	TCTCGACGCAGGACTCGGCTTG	684–705	1722	This study
2406 (R) <sup>e</sup>	<i>gag</i>	CTCCAATCCYCCTATCATTITTTGGTTTCC	2377–2406		This study
1832 (F)	<i>pol</i>	CAGCATGYCAGGGAGTRGGRGGACC	1832–1856	1751	This study
3583 (R)	<i>pol</i>	GGYTCTGRTAAATTTGATATGTCCATTG	3555–3583		This study
2078 (F)	<i>pol</i>	AGGCTAATTTTTAGGGAARATYTGCCCTCC	2078–2109	1461	This study
3539 (R)	<i>pol</i>	CTGTATTTCTGCTAYTAAGTCTTTTGATGG	3510–3539		This study
5955 (F)	<i>env</i>	GCTTAGGCATCTCCTATGGCA	5955–5975	3226	This study
9181 (R)	<i>env</i>	GTGTGTAGTTYTGCCAATCAGG	9160–9181		This study
6111 (F) <sup>e</sup>	<i>env</i>	TMATAGCAATAGTTGTGTGGACYATAG	6111–6137	2927	This study
JL88 (R) <sup>e</sup>	<i>env</i>	TAAGTCATTGGTCTTAAAGGTACCTG	9013–9038		32
<b>Sequencing primers</b>					
1173 (F)	<i>gag</i>	CAGYCAAAATTAYCCTATAGTGCA	1173–1196		This study
1985 (R)	<i>gag</i>	CCTTCYTTGCCACARTTGAAACAY	1962–1985		This study
2136 (F)	<i>pol</i>	YCAGARCAGACCAGAGCCAACAGCCCC	2136–2162		This study
2216 (F)	<i>pol</i>	AGGAGCMGAWAGACARG	2216–2232		This study
2454 (F)	<i>pol</i>	GGAMAWAARGCTATAGGTACAG	2454–2475		This study
2610 (R)	<i>pol</i>	CYTTTGGGCCATCCATTCC	2593–2610		This study
2650 (R)	<i>pol</i>	AATGCTTTTATITTYTCTTCTGTCAATGGC	2621–2650		This study
2734 (R)	<i>pol</i>	GCAAATAYTGAGTATTRTATGGATTTTCAGG	2703–2734		This study
3003 (F)	<i>pol</i>	GGATGGAAAGGATCACC	3003–3019		This study
3019 (R)	<i>pol</i>	GGTGATCCTTTCCATCC	3003–3019		This study
3462 (R)	<i>pol</i>	CTGCCARTTCTARYTCTGCTTC	3441–3462		This study
6438 (F)	<i>env</i>	CATGCCGTGTACCCACAGA	6438–6457		This study
6858 (F)	<i>env</i>	CCAATCCYATACATTATTGTGCYC	6858–6882		This study
8039 (R)	<i>env</i>	GGTGCARATGWGTTTTCCAGAGC	8017–8039		This study
8530 (R)	<i>env</i>	TGGTAGCTGAAGAGGCACAG	8511–8530		This study

<sup>a</sup>Reverse transcriptase, primary and secondary PCR primers, and sequencing primers name as appears in the text; orientation of the PCR primer is indicated in parentheses: F, forward; R, reverse.

<sup>b</sup>Y, indicates equal molar mixture of C and T; R, A, and G; M, A, and C; W, A, and T.

<sup>c</sup>Primer positions correspond to subtype B HIV-1 HXB2 strain (GenBank accession number K03455).

<sup>d</sup>Salminen *et al.*<sup>32</sup>


<sup>e</sup>Used also as sequencing primers as described in the text.

8039, 8530, JL88 for *env* (*gp160*). DNA sequence reactions were performed by the BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA) according to the manufacturer's recommendations. Samples were sequenced with the ABI 3130 genetic analyzer (Applied Biosystems, Foster City, CA). Samples exhibiting partial or extensive viral diversity by direct sequencing were subsequently cloned, using the TOPO TA cloning kit for sequencing (Invitrogen Corp., San Diego, CA) and sequenced as described above.

#### Determination of drug-resistance-associated mutations in protease, reverse transcriptase, *gag*, and *gp41*

Genotypic resistance mutations to antiretroviral drugs to protease and reverse transcriptase were determined using a genotyping in-house assay that analyzes *protease* and *RT* genes within M-group strains (Fig. 1). HIV-1 DNA sequences encoding 1461 bp of the *pol* (*protease and RT*) region were amplified from each sample by nested RT-PCR using extracted viral RNA (Fig. 1). Primers 1832 and 3583 were used in the first round of RT-PCR; the inner primers were 2078–3539 (Table 2). In the first round of RT-PCR, approximately 15  $\mu$ l of patient plasma RNA was used, as were 20 pmol of each

primer and Invitrogen SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity (Invitrogen Corp., San Diego, CA) in a 50- $\mu$ l volume. Amplification was carried out in an Eppendorf Master Cycler (Eppendorf, Hamburg, Germany). The thermocycling conditions were one cycle at 52°C for 1 h, one cycle at 94°C for 2 min, 40 cycles at 94°C for 15 s, 52°C for 30 s, 68°C for 2 min, and one cycle at 68°C for 5 min. In the second round of PCR, 3- $\mu$ l samples of primary reaction products were used, along with 20 pmol of each primer and 1.1X Platinum PCR SuperMix (Invitrogen Corp., San Diego, CA) in a 50- $\mu$ l volume. The amplification conditions were identical to those described for the second round of PCR in the nested PCR of *pol* (*protease and RT*). The DNA sequences of amplified products were determined by direct sequencing using the following sequencing primers: 2136, 2216, 2454, 2610, 2650, 2734, 3003, 3019, 3462, and 3539 (see Table 2 and Fig. 2). Genotypic resistance was defined as the presence of at least one resistance-related amino acid substitution as specified by the International AIDS Society (IAS)-USA<sup>33</sup> and the Stanford HIV Drug Resistance Database.<sup>34</sup> Assessment of the possible impact of transmitted drug resistance on the therapeutic response was performed using the Stanford drug-resistant algorithm.<sup>35</sup> *Gag* cleavage site-associated mutations (NC/p1/p6, corresponding to amino acids



**FIG. 1.** Schematic representation summarizes the amplification of the 5'-end-half *pol* region within HIV-1 M Group subtypes used in a novel genotypic drug-resistant assay of *protease* and *reverse transcriptase* described in this study. (A) The upper diagram summarizes the overall HIV-1 genetic organization exemplified by the HXB2 genome (GenBank accession number K03455). The beginning and end of each major genetic region are indicated by a corresponding number above and below the diagram, respectively, using the HXB2 numbering. The shaded area in the HIV-1 gene map indicates the *gag* (*p6*) and *pol* (*prot* and *p51 RT*) region amplified in the genotypic drug-resistant assay. (B) The lower scheme summarizes the nested RT-PCR designed for the amplification of *protease* and *RT* genes. Black arrows indicate the orientations and 5'-end-primer-binding positions of the primary (1832 and 3583) and secondary (2078 and 3539) PCR primers with respect to the HXB2 genome. The intermittent and solid cylinders indicate the product of the primary RT-PCR and secondary PCR, respectively.

428–454 of the HXB2 *gag* precursor protein) were analyzed from the Cypriot *gag* sequences as specified by Maguire *et al.*<sup>36</sup> and Nijhuis *et al.*<sup>37</sup> Fusion-inhibitor-associated mutations of gp41 (heptad repeat 1, corresponding to amino acids 30–51 of the HXB2 gp41) were analyzed from Cypriot gp41 sequences as specified by the IAS-USA<sup>33</sup> and Van Laethem *et al.*<sup>38</sup>

#### Phylogenetic tree analysis

We used DNA alignment, distance calculation, and phylogenetic tree construction programs from the Molecular Evolution Genetic Analysis (MEGA) software.<sup>39</sup> Patients' DNA sequences encoding the *pol*, *gag*, and *env* viral regions were aligned against corresponding sequences of genetically characterized HIV-1 strains obtained from the Los Alamos database<sup>1</sup> using the alignment method described in the MEGA program run with default conditions. Pairwise distance matrices were calculated using the Kimura two-parameter distance estimation approach with a transition/transversion ratio of 2.0 and phylogenetic trees were constructed using the neighbor-joining method. The consistency of the phylogenetic clustering was tested using bootstrap analysis with 100 replicates. Bootstrap values above 70 were considered adequate for subtype assignment. The subtype assignment was confirmed using the REGA algorithm.<sup>40</sup> GenBank accession numbers for control reference sequences in phylogenetic analyses are as follows: A1-94SE7253, AF069670; A1-9292UG037.1, U51190; A1-94Q23, AF004885; A1-98UG57136, AF484509; A2-

97CDKTB48, AF286238; A2-94CY017, AF286237; B-83HXB2, K03455; B-981058, AY331295; B-90BK132, AY173951; B-00671, AY423387; C-9292BR025.8, U52953; C-86ETH2220, U46016; C-04SK164B1, AY772699; C-95IN21068, AF067155; D-01A280, AY253311; D-9494UG114.1, U88824; D-83ELI, K03454; D-014412HAL, AY371157; F1-93VI850, AF077336; F1-93FIN9363, AF075703; F1-9393BR020-1, AF005494; F1-96MP411, AJ249238; F2-95MP255, AJ249236; F2-95MP257, AJ249237; F2-020016BBY, AY371158; F2-97CM53657, AF377956; G-93HH8793.1.1, AF061640; G-96DRCBL, AF084936; G-92NG083, U88826; G-93SE6165, AF061642; H-93VI997, AF190128; H-90056.1, AF005496; H-94VI991, AF190127; J-94SE9280.9, AF082394; J-93SE9173.3, AF082395; K-97EQTB11C, AJ249235; K-96MP535, AJ249239; 01AE-90CM240, U54771; and 02AG-IBNG, L39106.


#### Coreceptor usage

The coreceptor usage of HIV-1 was predicted from DNA sequences encoding the *env* (V3 loop) region using the Geno2pheno<sup>41</sup> and PSSM<sup>42</sup> coreceptor prediction algorithms running with default conditions.

## Results

#### Clinical and epidemiological features of the study patients

The study group consisted of 37 HIV-1-seropositive patients from the Cyprus Reference AIDS Clinic of Larnaca



**FIG. 2.** Schematic diagram summarizes the sequencing procedure of the *protease-RT pol* region. (A) A solid cylinder represents the final amplicon containing *gag* (*p6*) and *pol* (*prot* and *p51 RT*) regions derived from the RT-PCR procedure (Fig. 1). Black arrows indicate the orientations and 5'-end binding positions of the sequencing primers. (B) Gray cylinders indicate the sequence segments obtained from each sequencing primer. The beginning and end of each segment are indicated by a corresponding number above and below the diagram, respectively. DNA segments marked by asterisks are alternates: 2734 and 2650 can be used instead of 2610 and 3539 instead of 3462. (C) A solid cylinder represents the final aligned DNA sequence derived from all partial segments (corresponding to nucleotides 2253 to 3485 on the HXB2 genome) containing the full *protease* (codons 1 to 99) and partial *RT* (codons 1 to 312) genes. At the bottom, the diagram indicates the number of aligned nucleotides per nucleotide position from information derived from all partial sequence segments; dashed lines indicate the limit of aligned nucleotides per aligned nucleotide position used in the genotypic analysis.

National Hospital. Each patient is identified by a laboratory registration number ascending in chronological order of blood drawn. The study subjects represent 72% of the total number of newly HIV-1-diagnosed patients monitored at the clinic from 2003 until 2006 in Cyprus. The general demographic, epidemiological, and clinical features of all study subjects are summarized in Table 3. Among the 37 patients, 29 were male and 8 were female. Their median age was 34 years. Twenty-eight patients have asymptomatic infection, whereas nine have symptomatic infections. Two patients were coinfecting with hepatitis B virus (HBV) and three with hepatitis C virus (HCV). The median CD4<sup>+</sup> lymphocyte count was 363 cells/mm<sup>3</sup> and the median plasma HIV-load was 4.75 log HIV-1 RNA copies/ml. Twenty-four patients are Cypriots,

five are from sub-Saharan Africa, five from Eastern Europe, two from western Europe, and one from Asia. Of the patients, 18 were infected by homosexual/bisexual contact, 17 were infected by heterosexual contact, one was infected in an HIV-1 high prevalence country (Burkina-Faso), and for one the route of infection is unknown.

Epidemiological features varied among the 37 patients. Sixteen subjects were infected in Cyprus: eight men by homosexual contact and three men and five women by heterosexual contact. Four subjects were presumably infected in Greece by homosexual contact. One man was infected in Germany, one in the United Kingdom, and one in the United States by homosexual contact. Two men were infected in Cameroon, one heterosexually and one homosexually. One

TABLE 3. CHARACTERISTICS OF THE STUDY SUBJECTS

Characteristics <sup>a</sup>	Patients (N = 37)
Gender (%)	
Male	29 (78)
Female	8 (22)
Age (years) <sup>b</sup>	
Median (IQR)	34 (27–42)
Region of origin (%)	
Cyprus	24 (65)
Western Europe	2 (5)
Eastern Europe	5 (14)
Sub-Saharan Africa	5 (14)
Asia	1 (3)
Route of transmission (%)	
MSM	18 (49)
HSX	17 (46)
OHPC	1 (3)
N/A	1 (3)
CDC stage number (%)	
A	28 (76)
B	3 (8)
C	6 (16)
Plasma HIV-RNA (log copies/ml)	
Median (IQR)	4.75 (4.3–5.1)
CD4 count (cells/ml) <sup>c</sup>	
Median (IQR)	363 (199–565)
Subtype (%)	
A	14 (38)
B	13 (35)
C	5 (13)
D	1 (3)
CRF01_AE	1 (3)
CRF02_AG	3 (8)
Coinfection (%)	
HBV	2 (5.4)
HCV	3 (8.1)

<sup>a</sup>IQR, interquartile range.

<sup>b</sup>Information available for 35 patients.

<sup>c</sup>Information available for 34 patients.

man was infected in South Africa by homosexual contact. Two men were infected in Burkina-Faso, one by homosexual contact and the other by an unknown route of infection. One man was infected in Thailand by heterosexual contact. One heterosexual couple was infected in Georgia. One heterosexual couple was infected in Ethiopia. One heterosexual couple (the man is from the United Kingdom and the woman from Sweden) living in Cyprus reported that the place of infection is unknown. One patient was infected by homosexual contact whose place of infection is unknown and for one patient the route and place of infection are unknown.

#### PCR and DNA sequencing

Uncultured PBMCs and plasma from all subjects were HIV-1 positive by nested PCR in the *gag*, *pol* (*protease and RT*), and *env* (*gp160*) regions. The positive PCR combined with the extensive genetic diversity of the HIV-1 strains, as described in the phylogenetic analysis (Fig. 3), demonstrates that the newly designed PCR primers are suitable for diverse M-group strains. All HIV-1 PCR products were further analyzed by nucleotide sequencing analysis. The complete DNA sequences from *gag* and *pol* were derived by direct (population)

sequencing using PCR-amplified products from PBMC-extracted genomic DNA. The *env* regions in 10 patients were derived by direct sequencing, in 15 patients from *env* inserts of cloned PCR fragments, in five patients by RT-PCR from plasma-extracted HIV-1 RNA, and in seven patients no *env* sequences were obtained because of primer failure to bind to the DNA template.

#### Phylogenetic analysis

The molecular epidemiological relationship between DNA sequences encoding the *gag*, *pol*, and *env* regions was analyzed by nucleotide phylogenetic analysis. Three phylogenetic trees, one corresponding to each viral region, were constructed for the 37 study subjects on the basis of 37 derived *gag* and *pol* and 30 *env* DNA sequences (see Fig. 3A, B, and C, respectively). In addition to the sequences from Cyprus, 37 previously sequenced HIV-1 isolates from diverse global locations, encompassing all nine known subtypes (A through K) and two circulating recombinant forms (CRF), CRF01\_AE and CRF02\_AG, were also included in the analysis.


According to the constructed phylogenetic trees shown in Fig. 3, four distinct subtypes (A, B, C, and D) and two CRFs (CRF01\_AE and CRF02\_AG) were identified for the Cypriot sequences within the M group: subtype A, 14 sequences; subtype B, 13 sequences; subtype C, five sequences; subtype D, one sequence; CRF01\_AE, one sequence; and CRF02\_AG, three sequences. In the phylogenetic tree constructed based on *env* sequences (Fig. 3C), seven sequences classified previously as *gag* and *pol* are missing: subtype A, one sequence; subtype B, five sequences; and CRF02\_AG, one sequence. It is important to note that the Cypriot sequences in subtypes A (38% of patients), B (35%), C (13%), and CRF02\_AG (8%) have a relatively high average intrasubtype genetic diversity. The average (range) intrasubtype nucleotide divergence among the Cypriot *gag* sequences with subtype A is 11.0% (0.6 to 27.9%); within subtype B, 10.0% (3.2 to 16.2%); within subtype C, 10.3% (1.0 to 14.0%); and within CRF02\_AG, 12.6% (8.1 to 14.9%). This finding suggests that subtypes A, B, C, and CRF02\_AG were transmitted to Cyprus during the study period (2003 to 2006) by multiple sources, which is consistent with the epidemiological data of the study subjects presented in Table 1.

#### Genotypic drug resistance

There was no protease inhibitor (PI)-associated mutation observed in the untreated study population, but a number of minor PI-associated mutations (L10I, K20M/R, M36I, L63P/F/S/A/V, A71V/T, and V77I) were observed in 36 patients (97%). The amino acid substitution M36I was found in all non-B samples, while the amino acid substitutions K20R and L10I were observed in 14% and 9% of subtype A sequences, respectively. Furthermore, amino acid substitutions L63P and A71V were seen in 17 sequences (46%) of subtype B sequences and V77I was seen in 12 sequences (31%). Nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations were seen in one subtype B sequence (M41L/M mutation in CY010 patient) and in one subtype A sequence (M184V mutation in patient CY169). The M41L mutation is associated with potentially low resistance (PLR) to didanosine, abacavir, and tenofovir and low resistance (LR) to zidovudine and stavudine, whereas the M184V mutation is


(A)

*gag*




(B)

*pol* (protease and RT)







**FIG. 3.** Neighbor-joining phylogenetic trees for the nucleotide sequence of the *gag* region (A), the *pol* region (*prot and p51 RT*) (B), and the *env* region (*gp160*) (C) of HIV-1 strains obtained from newly diagnosed drug-naive patients in Cyprus, based on the Kimura two-parameter distance estimation method. In all trees representative reference sequences of HIV-1 subtypes (A–K) and CRF01\_AE, CRF02\_AG (shown in boldface) are included. The numbers indicated at several nodes are consensus bootstrap values out of 100 replications (only bootstrap values greater than 50% are denoted). The sequences determined in the study are shown in white on black boxes with a prefix CY for Cyprus and the number following denoting the laboratory code. The divergence between any two sequences is obtained by summing the horizontal branch length, using the scale at the lower left. The brackets on the right side of the trees indicate the determined subtypes as described in Results.

associated with high resistance (HR) to lamivudine and emtricitabine and PLR for abacavir. Furthermore, nonnucleoside reverse transcriptase inhibitor (NNRTI)-associated mutations were observed in one subtype C sequence (V179D mutation in CY004). The V179D mutation is associated with low-level (about 2-fold) resistance to nevirapine, delavirdine, and efavirenz and it has an impact on the sensitivity to etravirine when it coexists with other mutations.<sup>33,43</sup>

*Gag* cleavage site-associated mutations were analyzed from the 37 Cypriot *gag* sequences as previously established.<sup>36,37</sup> Genetic analysis of the *gag* sequences revealed that two subtype B sequences (CY013 and CY014) and one subtype A sequence (CY178) had the P453L (p1/p6 cleavage site) amino acid substitution previously shown to be linked with PI-associated drug resistance in combination with the presence of the protease 150V amino acid substitution.<sup>36,37</sup> Fusion inhibitor-associated mutations were analyzed from 33 Cypriot *env* sequences as previously established.<sup>33,38</sup> The *env* sequences from four patients (CY006, CY066, CY109, and CY177) were excluded due to incomplete sequencing as previously explained. Genetic analysis of the gp41 heptad repeat 1 (HR1) revealed that one subtype B sequence (CY005) had the L44M amino acid substitution, which is associated with resistance to the fusion inhibitor enfuvirtide (T20).<sup>33,38</sup>

#### Sequence analysis of *env* (V3 loop) region

Alignment of the predicted protein sequences of the V3 loop of *env* gp120 sequences from 36 Cypriot sequences was performed. For comparison, the consensus sequence from each subtype was also deduced (data not shown). The positions of the two cysteine residues in this region (corresponding to amino acid positions 296 and 331 of the HXB2 gp41) were conserved, suggesting a similar folding of this region of the protein. Thirty-one sequences have 35 amino acid residues, while five sequences (CY111, CY112, CY016, CY089, and CY166) have 34 amino acid residues, missing glycine (G) at position 24. All 36 sequences had a putative N-linked glycosylation site at the N-terminus of the V3 loop. Nine of 13 subtype B sequences had the GPGR tetrapeptide motif at the crest of the V3 loop, which is the most common motif found throughout subtype B sequences. However, in two subtype B sequences (CY005 and CY089), the first G in the GPGR motif was replaced by alanine (A), another nonpolar amino acid leading to the motif APGR. In other three B sequences (CY010, CY016, and CY035) the arginine (R) in the GPGR motif was replaced by serine (S), a polar amino acid, alanine (A), a nonpolar amino acid, and lysine (K), a basic amino acid, respectively. Additionally, the subtype B sequence CY159 had the motif RPRK. The tetrapeptide motifs at the tip of the loops of the 14 subtype A sequences were highly variable, containing 10 GPGQ, one RPGQ, and two GPRK. The five subtype C sequences had the GPGQ motif, as did the subtype D sequence and the CRF01\_AE and CRF02\_AG sequences.

The PSSM algorithm detected all the viruses as R5 (using CCR5 coreceptor). The Geno2pheno algorithm predicted 34 viruses as R5, and two (CY035 and CY111) as dual-tropic/mixed-tropics or X4 (using CXCR4 coreceptor). The two algorithms were in accordance in their capacity to detect, or not detect, R5 viruses in 34 of 36 cases (94.5%). The two samples detected as carrying dual-tropic/mixed-tropic or X4

viruses had a low CD4 cell count and high viral load, respectively (Table 1). It is important, however, to note that both interpretation coreceptor algorithms may not be fully compatible to non-B strains.

#### Discussion

In the period between January 2003 and December 2006, 52 persons were reported to be infected with HIV-1 in Cyprus, of which 65% were Cypriots and the rest were foreigners. Compared with the data already published by Kostrikis *et al.*, where the samples were studied with a heteroduplex mobility assay of the *env* (C2–V3) region,<sup>22</sup> the present study yields more detailed information about the epidemiological status of HIV infection in Cyprus among 72% of the newly diagnosed patients in the time period 2003–2006. Clearly, subtypes A and B are dominant, followed by subtypes C, CRF02\_AG, D, and CRF01\_AE, strains that dominate the global epidemic. The frequency of non-B subtypes entering Cyprus (65%) is higher than that reported a decade ago (40%).<sup>22</sup> This finding reinforces the observed trend of the increasing prevalence of HIV-1 non-B subtypes among newly diagnosed patients in Europe.<sup>24</sup> This phenomenon is most likely due to a large number of immigrants from African and eastern European countries, where non-B subtypes are predominant; this has also been observed in other European countries,<sup>18,27,44–51</sup> countries of the Mediterranean region,<sup>17,52</sup> and in the United States.<sup>4,53</sup> The present study represents a significant contribution to the molecular epidemiology of HIV-1 infection in Europe and the Mediterranean countries and to the evaluation of the movement of various strains across geographic regions.

The phylogenetic trees show that there are three distinct and divergent clusters within the A subtype, one in subtype B, one in subtype C, and one in CRF02\_AG. The average intrasubtype diversity (range) among six Cypriot *gag* sequences within subtype A (CY057, CY058, CY169, CY171, CY170, and CY173) is 5.1% (0.6–11.9%). The relatively low genetic diversity (5.1%) among these sequences in comparison with the overall intrasubtype diversity (11.0%) suggests that the isolates were derived from epidemiologically linked individuals. This finding is further reconfirmed by the branch topologies in the phylogenetic trees from the *gag*, *pol*, and *env* sequences (Fig. 3A, B, and C), the bootstrap values associated with the cluster (99 out of 100 replicates), and the epidemiological information provided by the study subjects. Indeed, this cluster of patients consists of three heterosexual couples: a couple from Georgia (CY057 and CY058) who reported being infected in Georgia, a man from Cyprus (CY171) and a woman from Georgia (CY169) who were infected in Cyprus, and a man from Cyprus (CY170) and a woman (CY173) from Ukraine who were infected in Cyprus.

This is the first time the prevalence and patterns of anti-retroviral drug resistance-associated mutations were estimated for a population in Cyprus in 2003–2006. A novel method for dealing with B- and non-B subtypes has been successfully established and used to determine transmitted drug resistance. Cyprus has one of the lowest levels of transmitted drug resistance (5.4%) worldwide,<sup>30</sup> similar to Brazil, Chile, Japan, Denmark, Slovenia, and Georgia,<sup>28,46,54–57</sup> and in contrast to Greece, The Netherlands, and Portugal.<sup>3,18,27</sup> No primary mutations conferring resistance to PIs or NNRTIs were observed in

the Cyprus isolates, but a high rate of minor mutations was seen. Two patients (5.4%) had RT mutations associated with reduced susceptibility to the NRTIs. The results of this study support the need for routine resistance testing before the initiation of antiretroviral therapy for HIV patients in Cyprus following the European and IAS-USA guidelines, which recommend resistance testing in chronically infected drug-naive patients when the regional prevalence of resistance is  $\geq 10\%$  and  $\geq 5\%$ , respectively.<sup>58,59</sup> This is also supported by the increase in newly diagnosed HIV-1-infected patients in 2007 in relation to the total number of newly diagnosed HIV-1-infected patients in 2006. Therefore, there should be more active surveillance of resistance-associated mutations in untreated individuals in order to recognize, as soon as possible, any significant change that may affect their future clinical management, as well as to plan and optimize the first line regimen and estimate of prevalence of resistance over time.

The gp41 HR1 domain is well conserved in all study subjects. However, one newly diagnosed patient out of 33 (3%) had one of the currently known mutations in the HR1 region associated with resistance to T20. The incidence of genotypic changes at amino acids 36–45 among T20-naive populations is low, demonstrating a natural conservation of the motif.<sup>60,61</sup> Our results reinforce the suggestion of testing the HR1 region with population sequencing before commencing therapy with T20.

Tropism predictions of the newly diagnosed patients were in accordance with the literature data, where it is well known that R5 variants are generally responsible for the establishment of primary infection.<sup>62</sup> To effectively monitor patient response to the new coreceptor inhibitors, such as maraviroc, a sequence-based method for predicting *coreceptor* usage should be performed prior to and after administration of the inhibitors in correlation with the CD4 cell count and viral load.<sup>62,63</sup>

In conclusion, the results presented in this report provide important information about HIV-1 genetic variation in Cyprus. A high genetic diversity of subtypes and CRFs in *gag*, *pol* (*protease and RT*), and *env* (*gp160*) sequences indicates multiple introductions of distinct viral variants. New data are provided for HIV-1 variation associated with resistance to protease, RT, and entry inhibitors: 5.4% had resistant mutations associated with NRTIs and 3% presented a T20-resistant mutation. Cyprus has a low prevalence of transmitted resistance compared with most other European countries in the *pol* (*protease and RT p51*) region, but the presence of resistant mutations in the genetic area of gp41 reveals that the newly diagnosed patients have a very heterogeneous genetic profile. Furthermore, these results provide important baselines prior to the introduction of combined antiretroviral therapy to newly diagnosed individuals in Cyprus.

### Sequence Data

GenBank accession numbers for the sequences obtained in this study are as follows: *gag* sequences, EU673411–EU673447; *pol*, EU673374–EU673410 and *env*, EU668962–EU668991.

### Acknowledgments

We thank all participating subjects from the Larnaca General Hospital AIDS Clinic, E. Lazarou, C. Kasapis, I. Christodoulou, M. Christophina, the Cyprus Ministry of Health, and the Cyprus National Bioethics Committee for valuable assis-

tance; S. Gilliland and E. Yiakoumi for data preparation; and E. Loizidou for helpful discussions. This work was supported by grants from the European Commission (FP6-014822, QLK2-CT-2001-01344, and LSHP-CT-2006-518211), the Cyprus Research Promotion Foundation (Health/0104/22), the University of Cyprus (8037-3/312-25004 and 837-25011), and the Birch Biomedical Research LLC (3416-25017) awarded to L.G. Kostrikis.

### Disclosure Statement

No competing financial interests exist.

### References

- Leitner T, Korber B, Daniels M, Calef C, and Foley B: HIV-1 subtype and circulating recombinant form (CRF) reference sequences, 2005. Los Alamos National Laboratory, Los Alamos, NM, 2005.
- Peeters M, Toure-Kane C, and Nkengasong JN: Genetic diversity of HIV in Africa: Impact on diagnosis, treatment, vaccine development and trials. *AIDS* 2003;17:2547–2560.
- Wensing AM and Boucher CA: Worldwide transmission of drug-resistant HIV. *AIDS Rev* 2003;5:140–155.
- Bennett D: HIV-1 genetic diversity surveillance in the United States. *J Infect Dis* 2005;192:4–9.
- Anastassopoulou CG and Kostrikis LG: Global genetic variation of HIV-1 infection. *Curr HIV Res* 2006;4:365–373.
- McCutchan FE: Global epidemiology of HIV. *J Med Virol* 2006;78:S7–S12.
- Gobbers E, Franssen K, Oosterlaken T, Janssens W, Heyndrickx L, Ivens T, *et al.*: Reactivity and amplification efficiency of the NASBA HIV-1 RNA amplification system with regard to different HIV-1 subtypes. *J Virol Methods* 1997;66:293–301.
- Chew CB, Herring BL, Zheng F, Browne C, Saksena NK, Cunningham AL, *et al.*: Comparison of three commercial assays for the quantification of HIV-1 RNA in plasma from individuals infected with different HIV-1 subtypes. *J Clin Virol* 1999;14:87–94.
- Parekh B, Phillips S, Granade TC, Baggs J, Hu DJ, and Renshaw R: Impact of HIV type 1 subtype variation on viral RNA quantitation. *AIDS Res Hum Retroviruses* 1999;15:133–142.
- Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, Panteleeff D, *et al.*: Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. *J Clin Microbiol* 2000;38:2688–2695.
- Jenny-Avital ER and Beatrice ST: Erroneously low or undetectable plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid load, determined by polymerase chain reaction, in West African and American patients with non-B subtype HIV-1 infection. *Clin Infect Dis* 2001;32:1227–1230.
- Gottesman BS, Grossman Z, Lorber M, Levi I, Shitrit P, Katzir M, *et al.*: Comparative performance of the Amplicor HIV-1 Monitor Assay versus NucliSens EasyQ in HIV subtype C-infected patients. *J Med Virol* 2006;78:883–887.
- Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, *et al.*: Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. *Nat Med* 2007;13:100–106.
- Nickle DC, Rolland M, Jensen MA, Pond SL, Deng W, Seligman M, *et al.*: Coping with viral diversity in HIV vaccine design. *PLoS Comput Biol* 2007;3:e75.

15. Rolland M, Nickle DC, and Mullins JI: HIV-1 group M conserved elements vaccine. *PLoS Pathog* 2007;3:e157.
16. Fischer W, Liao HX, Haynes BF, Letvin NL, and Korber B: Coping with viral diversity in HIV vaccine design: A response to Nickle et al. *PLoS Comput Biol* 2008;4:e15; author reply e25.
17. Grossman Z, Lorber M, Maayan S, Bar-Yacov N, Levy I, Averbuch D, et al.: Drug-resistant HIV infection among drug-naïve patients in Israel. *Clin Infect Dis* 2005;40:294–302.
18. Paraskevis D, Magiorkinis E, Katsoulidou A, Hatzitheodorou E, Antoniadou A, Papadopoulos A, et al.: Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. *Virus Res* 2005;112:115–122.
19. Traboulsi R, Kanafani ZA, Nakib M, and Kanj SS: Epidemiology of HIV infection in Lebanon. Data from 1985–2005. *J Med Liban* 2006;54:61–64.
20. Yilmaz G, Midilli K, Turkoglu S, Bayraktaroglu Z, Kuskucu AM, Ozkan E, et al.: Genetic subtypes of human immunodeficiency virus type 1 (HIV-1) in Istanbul, Turkey. *Int J Infect Dis* 2006;10:286–290.
21. Chemtob D and Grossman Z: Epidemiology of adult and adolescent HIV infection in Israel: A country of immigration. *Int J STD AIDS* 2004;15:691–696.
22. Kostrikis LG, Bagdades E, Cao Y, Zhang L, Dimitriou D, and Ho DD: Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: Identification of a new subtype designated subtype I. *J Virol* 1995;69:6122–6130.
23. Gao F, Robertson DL, Carruthers CD, Li YY, Bailes E, Kostrikis LG, et al.: An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G, and I). *J Virol* 1998;72:10234–10241.
24. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Ballotta C, Boeri E, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. *J Infect Dis* 2005;192:958–966.
25. Babic DZ, Zelnikar M, Seme K, Vandamme AM, Snoeck J, Tomazic J, et al.: Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000–2004. *Virus Res* 2006;118:156–163.
26. Geretti AM: Epidemiology of antiretroviral drug resistance in drug-naïve persons. *Curr Opin Infect Dis* 2007;20:22–32.
27. Palma AC, Araujo F, Duque V, Borges F, Paixao MT, and Camacho R: Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. *Infect Genet Evol* 2007;7:391–398.
28. Rios M, Delgado E, Perez-Alvarez L, Fernandez J, Galvez P, de Parga EV, et al.: Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. *J Med Virol* 2007;79:647–656.
29. Sagir A, Oette M, Kaiser R, Daumer M, Fatkenheuer G, Rockstroh JK, et al.: Trends of prevalence of primary HIV drug resistance in Germany. *J Antimicrob Chemother* 2007;60:843–848.
30. Booth CL and Geretti AM: Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. *J Antimicrob Chemother* 2007;59:1047–1056.
31. The SPREAD programme: Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. *AIDS* 2008;22:625–635.
32. Salminen MO, Carr JK, Robertson DL, Hegerich P, Gotte D, Koch C, et al.: Evolution and probable transmission of intersubtype recombinant human immunodeficiency virus type 1 in a Zambian couple. *J Virol* 1997;71:2647–2655.
33. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al.: Update of the drug resistance mutations in HIV-1: 2007. *Top HIV Med* 2007;15:119–125.
34. Shafer RW: Rationale and uses of a public HIV drug-resistance database. *J Infect Dis* 2006;194(Suppl. 1):S51–58.
35. Stanford HIV Resistance Database: Genotypic resistance interpretation algorithm (HIVdb program: Sequence analysis). <http://hivdb.stanford.edu>.
36. Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, et al.: Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants *in vivo* and cause reduction of sensitivity to amprenavir and improved viral fitness *in vitro*. *J Virol* 2002;76:7398–7406.
37. Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, et al.: A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. *PLoS Med* 2007;4:e36.
38. Van Laethem K, Schrooten Y, Lemey P, Van Wijngaerden E, De Wit S, Van Ranst M, et al.: A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. *J Virol Methods* 2005;123:25–34.
39. Tamura K, Dudley J, Nei M, and Kumar S: MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. *Mol Biol Evol* 2007;24:1596–1599.
40. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. *Bioinformatics* 2005;21:3797–3800.
41. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, et al.: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. *Antiviral Ther* 2007;12:1097–1106.
42. Jensen MA, Li FS, van't Wout AB, Nickle DC, Shriner D, He HX, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 *env* V3 loop sequences. *J Virol* 2003;77:13376–13388.
43. Parkin NT, Gupta S, Chappey C, and Petropoulos CJ: The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. *Antimicrob Agents Chemother* 2006;50:351–354.
44. Alaeus A, Leitner T, Lidman K, and Albert J: Most HIV-1 genetic subtypes have entered Sweden. *AIDS* 1997;11:199–202.
45. Chaix ML, Descamps D, Harzic M, Schneider V, Deveau C, Tamalet C, et al.: Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. *AIDS* 2003;17:2635–2643.
46. Jorgensen LB, Christensen MB, Gerstoft J, Mathiesen LR, Obel N, Pedersen C, et al.: Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. *Scand J Infect Dis* 2003;35:800–807.
47. Maljkovic I, Wilbe K, Solver E, Alaeus A, and Leitner T: Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naïve patients infected with subtypes A, B, C, D, G, U, and CRF01\_AE. *AIDS Res Hum Retroviruses* 2003;19:989–997.

48. Deroo S, Robert I, Fontaine E, Lambert C, Plessier JM, Arendt V, *et al.*: HIV-1 subtypes in Luxembourg, 1983–2000. *AIDS* 2002;16:2461–2467.
49. Esteves A, Parreira R, Venenno T, Franco M, Piedade J, De Sousa JG, *et al.*: Molecular epidemiology of HIV type 1 infection in Portugal: High prevalence of non-B subtypes. *AIDS Res Hum Retroviruses* 2002;18:313–325.
50. Fleury H, Recordon-Pinson P, Caumont A, Faure M, Roques P, Plantier JC, *et al.*: HIV type 1 diversity in France, 1999–2001: Molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. *AIDS Res Hum Retroviruses* 2003;19:41–47.
51. Snoeck J, Van Laethem K, Hermans P, Van Wijngaerden E, Derdelinckx I, Schrooten Y, *et al.*: Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983–2001. *J Acquir Immune Defic Syndr* 2004;35:279–285.
52. Bouzeghoub S, Jauvin V, Recordon-Pinson P, Garrigue I, Amrane A, Belabbes EH, *et al.*: High diversity of HIV type 1 in Algeria. *AIDS Res Hum Retroviruses* 2006;22:367–372.
53. Brodine SK, Shaffer RA, Starkey MJ, Tasker SA, Gilcrest JL, Louder MK, *et al.*: Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. *Ann Intern Med* 1999;131:502–506.
54. Babic DZ, Poljak M, Seme K, Tomazic J, and Vidmar L: Molecular epidemiology of HIV-1 subtypes based on analysis of pol sequences in Slovenia, 1996–2005. *J Med Virol* 2006;78:997–1002.
55. Gatanaga H, Ibe S, Matsuda M, Yoshida S, Asagi T, Kondo M, *et al.*: Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. *Antiviral Res* 2007;75:75–82.
56. Zarandia M, Tsertsvadze T, Carr JK, Nadai Y, Sanchez JL, and Nelson AK: HIV-1 genetic diversity and genotypic drug susceptibility in the Republic of Georgia. *AIDS Res Hum Retroviruses* 2006;22:470–476.
57. Rodrigues R, Scherer LC, Oliveira CM, Franco HM, Sperhacke RD, Ferreira JL, *et al.*: Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. *Virus Res* 2006;116:201–207.
58. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, *et al.*: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. *Clin Infect Dis* 2003;37:113–128.
59. Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bachelier L, *et al.*: Updated European recommendations for the clinical use of HIV drug resistance testing. *Antiviral Ther* 2004;9:829–848.
60. Greenberg ML and Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. *J Antimicrob Chemother* 2004;54:333–340.
61. Roman F, Gonzalez D, Lambert C, Deroo S, Fischer A, Baurith T, *et al.*: Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naïve patients infected with subtype B and non-B HIV-1 strains. *J Acquir Immune Defic Syndr* 2003;33:134–139.
62. Van Baelen K, Vandenbroucke I, Rondelez E, Van Eygen V, Vermeiren H, and Stuyver LJ: HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. *J Virol Methods* 2007;146:61–73.
63. Soulie C, Derache A, Aime C, Marcelin AG, Carcelain G, Simon A, *et al.*: Comparison of two genotypic algorithms to determine HIV-1 tropism. *HIV Med* 2008;9:1–5.

Address reprint requests to:

Leondios G. Kostrikis  
Department of Biological Sciences  
University of Cyprus  
75 Kallipoleos Avenue, P.O. Box 20537  
1678 Nicosia, Cyprus

E-mail: lkostrik@ucy.ac.cy



**This article has been cited by:**

1. Ioanna Kousiappa , David A.M.C. Van De Vijver , Leondios G. Kostrikis . 2009. Near Full-Length Genetic Analysis of HIV Sequences Derived from Cyprus: Evidence of a Highly Polyphyletic and Evolving InfectionNear Full-Length Genetic Analysis of HIV Sequences Derived from Cyprus: Evidence of a Highly Polyphyletic and Evolving Infection. *AIDS Research and Human Retroviruses* **25**:8, 727-740. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]